stoxline Quote Chart Rank Option Currency Glossary
  
Altimmune, Inc. (ALT)
7.6668  -0.013 (-0.17%)    07-12 12:22
Open: 7.79
High: 8
Volume: 1,218,927
  
Pre. Close: 7.68
Low: 7.63
Market Cap: 544(M)
Technical analysis
2024-07-12 11:47:42 AM
Short term     
Mid term     
Targets 6-month :  9.91 1-year :  11.58
Resists First :  8.48 Second :  9.91
Pivot price 6.93
Supports First :  6.72 Second :  5.63
MAs MA(5) :  7.32 MA(20) :  6.72
MA(100) :  8.13 MA(250) :  6.25
MACD MACD :  0.1 Signal :  -0.1
%K %D K(14,3) :  67.6 D(3) :  59.3
RSI RSI(14): 59.8
52-week High :  14.84 Low :  2.08
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ALT ] has closed below upper band by 8.6%. Bollinger Bands are 38% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.03 - 8.06 8.06 - 8.09
Low: 7.34 - 7.36 7.36 - 7.39
Close: 7.63 - 7.67 7.67 - 7.72
Company Description

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Headline News

Thu, 11 Jul 2024
Institutional investors are Altimmune, Inc.'s (NASDAQ:ALT) biggest bettors and were rewarded after last week's US$62m market cap gain - Simply Wall St

Wed, 10 Jul 2024
Commonwealth Equity Services LLC Raises Position in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Fri, 05 Jul 2024
FINAL ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - AccessWire

Wed, 03 Jul 2024
ALT DEADLINE FRIDAY: ROSEN, GLOBAL INVESTOR COUNSEL, - GlobeNewswire

Tue, 02 Jul 2024
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - PR Newswire

Fri, 28 Jun 2024
Class Action Lawsuit against Altimmune, Inc. (NASDAQ:ALT) - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 71 (M)
Held by Insiders 7.039e+007 (%)
Held by Institutions 0.7 (%)
Shares Short 23,060 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -8.809e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -535 %
Return on Assets (ttm) 879.9 %
Return on Equity (ttm) -29.5 %
Qtrly Rev. Growth 410000 %
Gross Profit (p.s.) -692.73
Sales Per Share -495.1
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -73 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 0.34
Stock Dividends
Dividend 0
Forward Dividend 2.314e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android